BACKGROUND AND OBJECTIVES: Two HALT PKD trials will investigate interventions that potentially slow kidney disease progression in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. Studies were designed in early and later stages of ADPKD to assess the impact of intensive blockade of the renin-angiotensin-aldosterone system and level of BP control on progressive renal disease. Design, settings, participants, and measurements: PKD-HALT trials are multicenter, randomized, double-blind, placebo-controlled trials studying 1018 hypertensive ADPKD patients enrolled over 3 yr with 4 to 8 yr of follow-up. In study A, 548 participants, estimated GFR (eGFR) of >60 ml/min per 1.73 m(2) were randomized to one of four arms in a 2-by-2 design: combination angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) therapy versus ACEi monotherapy at two levels of BP control. In study B, 470 participants, eGFR of 25 to 60 ml/min per 1.73 m2 compared ACEi/ARB therapy versus ACEi monotherapy, with BP control of 120 to 130/70 to 80 mmHg. Primary outcomes of studies A and B are MR-based percent change kidney volume and a composite endpoint of time to 50% reduction of baseline estimated eGFR, ESRD, or death, respectively. RESULTS: This report describes design issues related to (1) novel endpoints such as kidney volume, (2) home versus office BP measures, and (3) the impact of RAAS inhibition on kidney and patient outcomes, safety, and quality of life. CONCLUSIONS: HALT PKD will evaluate potential benefits of rigorous BP control and inhibition of the renin-angiotensin-aldosterone system on kidney disease progression in ADPKD.
RCT Entities:
BACKGROUND AND OBJECTIVES: Two HALT PKD trials will investigate interventions that potentially slow kidney disease progression in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. Studies were designed in early and later stages of ADPKD to assess the impact of intensive blockade of the renin-angiotensin-aldosterone system and level of BP control on progressive renal disease. Design, settings, participants, and measurements: PKD-HALT trials are multicenter, randomized, double-blind, placebo-controlled trials studying 1018 hypertensiveADPKDpatients enrolled over 3 yr with 4 to 8 yr of follow-up. In study A, 548 participants, estimated GFR (eGFR) of >60 ml/min per 1.73 m(2) were randomized to one of four arms in a 2-by-2 design: combination angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) therapy versus ACEi monotherapy at two levels of BP control. In study B, 470 participants, eGFR of 25 to 60 ml/min per 1.73 m2 compared ACEi/ARB therapy versus ACEi monotherapy, with BP control of 120 to 130/70 to 80 mmHg. Primary outcomes of studies A and B are MR-based percent change kidney volume and a composite endpoint of time to 50% reduction of baseline estimated eGFR, ESRD, or death, respectively. RESULTS: This report describes design issues related to (1) novel endpoints such as kidney volume, (2) home versus office BP measures, and (3) the impact of RAAS inhibition on kidney and patient outcomes, safety, and quality of life. CONCLUSIONS: HALT PKD will evaluate potential benefits of rigorous BP control and inhibition of the renin-angiotensin-aldosterone system on kidney disease progression in ADPKD.
Authors: Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Svend Strandgaard; Anne-Lise Kamper; Giuseppe Maschio; Gavin Becker; Ronald D Perrone; Andrew S Levey Journal: Kidney Int Date: 2005-01 Impact factor: 10.612
Authors: Timothy W Doulton; Anand K Saggar-Malik; Feng J He; Christine Carney; Nirmala D Markandu; Guiseppe A Sagnella; Graham A MacGregor Journal: J Hypertens Date: 2006-05 Impact factor: 4.844
Authors: Sandro Rossetti; Mark B Consugar; Arlene B Chapman; Vicente E Torres; Lisa M Guay-Woodford; Jared J Grantham; William M Bennett; Catherine M Meyers; Denise L Walker; Kyongtae Bae; Qin Jean Zhang; Paul A Thompson; J Philip Miller; Peter C Harris Journal: J Am Soc Nephrol Date: 2007-06-20 Impact factor: 10.121
Authors: Ivana Y Kuo; Andrea T Kwaczala; Lily Nguyen; Kerry S Russell; Stuart G Campbell; Barbara E Ehrlich Journal: Proc Natl Acad Sci U S A Date: 2014-11-03 Impact factor: 11.205
Authors: Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone Journal: N Engl J Med Date: 2014-11-15 Impact factor: 91.245
Authors: Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman Journal: N Engl J Med Date: 2014-11-15 Impact factor: 91.245
Authors: Anna S Nikonova; Alexander Y Deneka; Anna A Kiseleva; Vladislav Korobeynikov; Anna Gaponova; Ilya G Serebriiskii; Meghan C Kopp; Harvey H Hensley; Tamina N Seeger-Nukpezah; Stefan Somlo; David A Proia; Erica A Golemis Journal: FASEB J Date: 2018-01-10 Impact factor: 5.191
Authors: Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres Journal: Am J Kidney Dis Date: 2018-01-03 Impact factor: 8.860
Authors: Michel Chonchol; Berenice Gitomer; Tamara Isakova; Xuan Cai; Isidro Salusky; Renata Pereira; Kaleab Abebe; Vicente Torres; Theodor I Steinman; Jared J Grantham; Arlene B Chapman; Robert W Schrier; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2017-07-13 Impact factor: 8.237